Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Where Private Medtech Investments Dollars Went in 2010

This article was originally published in Start Up

Executive Summary

Overall in 2010, caution was the watchword for private investors, placing fewer dollars in fewer medtech deals compared to 2009. A total of $1.86 billion in private money was raised by medical device companies in 2010, a big drop from the $2.86 billion placed in the industry in 2009. Deal volume was down commensurately; there were 139 private medical device financings, compared to 207 in 2009. Investment dollars were apportioned, for the most part, in the usual fashion, with the largest proportion going into cardiovascular deals, followed by orthopedics. There were some surprises however, as a few categories, once avoided like the plaque, showed new investor interest.
Advertisement

Related Content

TCT 2010: TAVI Takes Center Stage
Noninvasive Body Contouring Begins To Take Shape
TriVascular's Sequel Could Be a Blockbuster
Medtronic Catapults Into Transcatheter Valve Market With Billion-Dollar Buys

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC092064

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel